Top

Published in:

Open Access 01-06-2017

Benzene and 2-ethyl-phthalate induce proliferation in normal rat pituitary cells

Authors: Laura Tapella, Antonella Sesta, Maria Francesca Cassarino, Valentina Zunino, Maria Graziella Catalano, Francesca Pecori Giraldi

Published in: Pituitary | Issue 3/2017

Abstract

Purpose

Endocrine disruptors are known to modulate a variety of endocrine functions and increase the risk for neoplasia. Epidemiological data reported increased prevalence of pituitary tumors in high industrial areas while genotyping studies showed that mutations in the aryl hydrocarbon receptor (AhR) interacting protein (AIP)—chaperone to the dioxin ligand AhR—gene are linked to predisposition to pituitary tumor development. Aim of the present study was to establish whether endocrine pollutants can induce cell proliferation in normal rat pituitary cells.

Methods

Pituitary primary cultures were incubated with 250, 650 and 1250 pM benzene or 2-ethyl-phthalate for up to 96 h and viability, energy content and cell proliferation assessed. Expression of pituitary tumor transforming gene (PTTG), cyclin D1 (Ccnd1), AhR and AIP was quantified by RT-qPCR.

Results

Incubation with benzene or 2-ethyl-phthalate increased viability and energy content in pituitary cells. The endocrine disruptors also increased cell proliferation as well as Ccnd1 and PTTG expression. Increased AhR and AIP expression was observed after incubation with the two pollutants.

Conclusions

Our findings indicate that benzene and 2-ethyl-phthalate activate AhR/AIP expression and stimulate proliferation in normal rat pituitary cells. This study is the first demonstration that pollutants can induce normal pituitary cells to proliferate and provides a link between epidemiological and genomic findings in pituitary tumors.

Available only for authorised users

Kabir ER, Rahman MS, Rahman I (2015) A review on endocrine disruptors and their possible impacts on human health. Environ Toxicol Pharmacol 40:241–258CrossRefPubMed

Gore AC (2015) Neuroendocrine targets of endocrine disruptors. Hormones 9:16–27CrossRef

Gore AC, Chappell VA, Fenton SE, Flaws JA, Nadal A, Prins GS, Toppari J, Zoeller RT (2015) EDC-2: the endocrine society’s second scientific statement on endocrine-disrupting chemicals. Endocr Rev 36:E1–E150CrossRefPubMedPubMedCentral

Schug TT, Johnson AF, Birnbaum LS, Colborn T, Guillette LJ Jr, Crews DP, Collins T, Soto AM, Vom Saal FS, McLachlan JA, Sonnenschein C, Heindel JJ (2016) Minireview: endocrine disruptors: past lessons and future directions. Mol Endocrinol 30:833–847CrossRefPubMed

Hampl R, Kubatova J, Starka L (2016) Steroids and endocrine disruptors—history, recent state of art and open questions. J Steroid Biochem Mol Biol 155:217–223CrossRefPubMed

Saracci R, Kogevinas M, Bertazzi PA, Bueno de Mesquita BH, Coggon D, Green LM, Kauppinen T, L’Abbe KA, Littorin M, Lynge E (1991) Cancer mortality in workers exposed to chlorophenoxy herbicides and chlorophenols. Lancet 338:1027–1032CrossRefPubMed

Rudel RA, Fenton SE, Ackerman JM, Euling SY, Makris SL (2011) Environmental exposures and mammary gland development: state of the science, public health implications, and research recommendations. Environ Health Perspect 119:1053–1061CrossRefPubMedPubMedCentral

Warner M, Mocarelli P, Samuels S, Needham L, Brambilla P, Eskenazi B (2011) Dioxin exposure and cancer risk in the Seveso Women’s Health Study. Environ Health Perspect 119:1700–1705CrossRefPubMedPubMedCentral

Hemminki K, Li X (2002) Cancer risks in second-generation immigrants to Sweden. Int J Cancer 99:229–237CrossRefPubMed

10.

Akthar FZ, Garabrant DH, Ketchum NS, Michalek JE (2004) Cancer in US Air Force veterans of the Vietnam war. J Occup Environ Med 46:123–136CrossRef

11.

Dairkee SH, Luciani-Torres MG, Moore DH, Goodson WH III (2013) Bisphenol-A-induced inactivation of the p53 axis underlying deregulation of proliferation kinetics, and cell death in non-malignant human breast epithelial cells. Carcinogenesis 34:703–712CrossRefPubMed

12.

Mlynarcikova A, Macho L, Fickova M (2013) Bisphenol A alone or in combination with estradiol modulates cell cycle- and apoptosis-related proteins and genes in MCF7 cells. Endocr Regul 47:189–199CrossRefPubMed

13.

Kang NH, Hwang KA, Lee HR, Choi DW, Choi KC (2013) Resveratrol regulates the cell viability promoted by 17beta-estradiol or bisphenol A via down-regulation of the cross-talk between estrogen receptor alpha and insulin growth factor-1 receptor in BG-1 ovarian cancer cells. Food Chem Toxicol 59:373–379CrossRefPubMed

14.

Maruyama S, Fujimoto N, Yin H, Ito A (1999) Growth stimulation of a rat pituitary cell line MtT/E-2 by environmental estrogens in vitro and in vivo. Endocr J 46:513–520CrossRefPubMed

15.

Fujimoto N (2003) Effects of environmental estrogenic compounds on growth of a transplanted estrogen responsive pituitary tumor cell line in rats. Food Chem Toxicol 41:1711–1717CrossRefPubMed

16.

Vinas R, Watson CS (2013) Mixtures of xenoestrogens disrupt estradiol-induced non-genomic signaling and downstream functions in pituitary cells. Environ Health 12:26–36CrossRefPubMedPubMedCentral

17.

Cossette LJ, Gaumond I, Martinoli MG (2002) Combined effect of xenoestrogens and growth factors in two estrogen-responsive cell lines. Endocrine 18:303–308CrossRefPubMed

18.

Isling LK, Boberg J, Jacobsen PR, Mandrup KR, Axelstad M, Christiansen S, Vinggaard AM, Taxvig C, Kortenkamp A, Hass U (2014) Late-life effects on rat reproductive system after developmental exposure to mixtures of endocrine disrupters. Reproduction 147:465–476CrossRefPubMed

19.

Cannavò S, Ferraù F, Ragonese M, Curtò L, Torre ML, Magistri M, Marchese A, Alibrandi A, Trimarchi F (2010) Increased prevalence of acromegaly in a highly polluted area. Eur J Endocrinol 163:509–513CrossRefPubMed

20.

Pesatori AC, Baccarelli A, Consonni D, Lania A, Beck-Peccoz P, Bertazzi PA, Spada A (2008) Aryl hydrocarbon receptor-interacting protein and pituitary adenomas: a population-based study on subjects exposed to dioxin after the Seveso, Italy, accident. Eur J Endocrinol 159:699–703CrossRefPubMed

21.

Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TM, Salmela PI, Paschke R, Gündogdu S, De Menis E, Mäkinen MJ, Launonen V, Karhu A, Aaltonen LA (2006) Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312:1228–1230CrossRefPubMed

22.

Poland A, Knutson J, Glover E (1985) Studies on the mechanism of action of halogenated aromatic hydrocarbons. Clin Physiol Biochem 3:147–154PubMed

23.

Safe S (2001) Molecular biology of the Ah receptor and its role in carcinogenesis. Toxicol Lett 120:1–7CrossRefPubMed

24.

Ghisari M, Long M, Tabbo A, Bonefeld-Jorgensen EC (2015) Effects of currently used pesticides and their mixtures on the function of thyroid hormone and aryl hydrocarbon receptor in cell culture. Toxicol Appl Pharmacol 284:292–303CrossRefPubMed

25.

Tran C, Richmond O, Aaron L, Powell JB (2013) Inhibition of constitutive aryl hydrocarbon receptor (AhR) signaling attenuates androgen independent signaling and growth in (C4-2) prostate cancer cells. Biochem Pharmacol 85:753–762CrossRefPubMed

26.

Pecori Giraldi F, Cavagnini F (1998) Corticotropin-releasing hormone is produced by rat corticotropes and modulates ACTH secretion in a paracrine/autocrine fashion. J Clin Invest 101:2478–2484CrossRefPubMed

27.

Pecori Giraldi F, Pesce S, Maroni P, Pagliardini L, Lasio G, Losa M, Cavagnini F (2010) Inhibitory effect of preproTRH(178-199) on ACTH secretion by human corticotrope tumours. J Neuroendocrinol 22:294–300CrossRefPubMed

28.

Nagami K, Kawashima Y, Kuno H, Kemi M, Matsumoto H (2002) In vitro cytotoxicity assay to screen compounds for apoptosis-inducing potential on lymphocytes and neutrophils. J Toxicol Sci 27:191–203CrossRefPubMed

29.

Rodrigues RM, Bouhifd M, Bories G, Sacco MG, Gribaldo L, Fabbri M, Coecke S, Whelan MP (2013) Assessment of an automated in vitro basal cytotoxicity test system based on metabolically-competent cells. Toxicol In Vitro 27:760–767CrossRefPubMed

30.

Heaney AP, Melmed S (1999) Pituitary tumour transforming gene: a novel factor in pituitary tumour formation. Bailliere’s Clin Endocrinol Metab 13:367–380

31.

Maqbool F, Mostafalou S, Bahadar H, Abdollahi M (2016) Review of endocrine disorders associated with environmental toxicants and possible involved mechanisms. Life Sci 145:265–273CrossRefPubMed

32.

Penaglotidou E, Zerva S, Mitsiou DJ, Alexis MN, Kitraki E (2014) Perinatal exposure to low-dose bisphenol A affects the neuroendocrine stress response. J Endocrinol 220:207–218CrossRef

33.

Murray TJ, Maffini MV, Ucci AA, Sonnenschein C, Soto AM (2007) Induction of mammary gland ductal hyperplasias and carcinoma in situ following fetal bisphenol A exposure. Reprod Toxicol 23:383–390CrossRefPubMed

34.

Prins GS, Birch L, Tang WY, Ho SM (2007) Developmental estrogen exposures predispose to prostate carcinogenesis with aging. Reprod Toxicol 23:374–382CrossRefPubMed

35.

Aflorei ED, Korbonits M (2014) Epidemiology and etiopathogenesis of pituitary adenomas. J Neurooncol 117:379–394CrossRefPubMed

36.

Ronchetti SA, Miler EA, Duvilanski BH, Cabilla JP (2013) Cadmium mimics estrogen-driven cell proliferation and prolactin secretion from anterior pituitary cells. PLoS ONE 8:e81101–e81113CrossRefPubMedPubMedCentral

37.

Steinmetz R, Brown NG, Allen DL, Bigsby RM, Ben JN (1997) The environmental estrogen bisphenol A stimulates prolactin release in vitro and in vivo. Endocrinology 138:1780–1786CrossRefPubMed

38.

Graham M, Cossette L, Gelinas S, Martinoli MG (2003) In vitro modulation of prolactin mRNA by toxaphene and 3,3′,4,4′-tetrachlorobiphenyl. Environ Res 92:207–212CrossRefPubMed

39.

Dang VH, Nguyen TH, Lee GS, Choi KC, Jeung EB (2009) In vitro exposure to xenoestrogens induces growth hormone transcription and release vie estrogen-receptor dependent pathways in rat pituitary GH3 cells. Steroids 74:707–714CrossRefPubMed

40.

Elango A, Shepherd B, Chen T (2006) Effects of endocrine disrupters on the expression of growth hormone and prolactin mRNA in the rainbow trout pituitary. Gen Comp Endocrinol 145:116–127CrossRefPubMed

41.

Dirtu AC, Niessen SJM, Jorens PG, Covaci A (2013) Organohalogenated contaminants in domestic cats’ plasma in relation to spontaneous acromegaly and type 2 diabetes mellitus: a clue for endocrine disruption in humans? Environ Int 57–58:60–67CrossRefPubMed

42.

Feldman D, Krishnan A (1995) Estrogens in unexpected places: possible implications for researchers and consumers. Environ Health Perspect 103(Suppl 7):129–133CrossRefPubMedPubMedCentral

43.

Kiyama R, Wada-Kiyama Y (2015) Estrogenic endocrine disruptors: molecular mechanisms of action. Environ Int 83:11–40CrossRefPubMed

44.

Kumar N, Sharan S, Srivastava S, Roy P (2014) Assessment of estrogenic potential of diethyl phthalate in female reproductive system involving both genomic and non-genomic actions. Reprod Toxicol 49:12–26CrossRefPubMed

45.

Dang VH, Nguyen TH, Choi KC, Jeung EB (2007) A calcium-binding protein, Calbindin-D9k, is regulated through an estrogen-receptor-mediated mechanism following xenoestrogen exposure in the GH3 cell line. Toxicol Sci 92:408–415CrossRef

46.

Mulero-Navarro S, Fernandez-Salguero PM (2016) New trends in aryl hydrocarbon receptor biology. Front Cell Dev Biol 4:45–59CrossRefPubMedPubMedCentral

47.

Trivellin G, Korbonits M (2011) AIP and its interacting partners. J Endocrinol 210:137–155CrossRefPubMed

48.

Beckers A, Aaltonen LA, Daly AF, Karhu A (2013) Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev 34:239–277CrossRefPubMedPubMedCentral

49.

Jaffrain-Rea ML, Angelini M, Gargano D, Tichomirowa MA, Daly AF, Vanbellinghen JF, D’Innocenzo E, Barlier A, Giangaspero F, Esposito V, Ventura L, Arcella A, Theodoropoulou M, Naves LA, Fajardo C, Zacharieva S, Rohmer V, Brue T, Gulino A, Cantore G, Alesse E, Beckers A (2009) Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocr Relat Cancer 16:1029–1043CrossRefPubMed

50.

Heliövaara E, Raitila A, Launonen V, Paetau A, Arola J, Lehtonen H, Sane T, Weil RJ, Vierimaa O, Salmela P, Tuppurainen K, Mäkinen M, Aaltonen LA, Karhu A (2009) The expression of AIP-related molecules in elucidation of cellular pathways in pituitary adenomas. Am J Pathol 175:2501–2507CrossRefPubMedPubMedCentral

51.

Hernandez-Ramirez LC, Martucci F, Morgan RM, Trivellin G, Tilley D, Ramos-Guajardo N, Iacovazzo D, D’Acquisto F, Prodromou C, Korbonits M (2016) Rapid proteasomal degradation of mutant proteins is the primary mechanism leading to tumorigenesis in patients with missense AIP mutations. J Clin Endocrinol Metab 101:3144–3154CrossRefPubMedPubMedCentral

52.

Lecoq AL, Viengchareun S, Hage M, Bouligand J, Young J, Boutron A, Zizzari P, Lombes M, Chanson P, Kamenicky P (2016) AIP mutations impair AhR signaling in pituitary adenoma patients fibroblasts and in GH3 cells. Endocr Relat Cancer 23:433–443CrossRefPubMed

53.

Cazabat L, Guillaud-Bataille M, Bertherat J, Raffin-Sanson ML (2009) Mutations of the gene for the aryl hydrocarbon receptor-interacting protein in pituitary adenomas. Horm Res 71:132–141CrossRefPubMed

54.

Martucci F, Trivellin G, Korbonits M (2012) Familial isolated pituitary adenomas: an emerging clinical entity. J Endocrinol Invest 35:1003–1014CrossRefPubMed

55.

Cannavò S, Ferrau F, Ragonese M, Romeo PD, Torre ML, Puglisi S, De Menis E, Arnaldi G, Salpietro C, Cotta OR, Albani A, Ruggeri RM, Trimarchi F (2014) Increased frequency of the rs2066853 variant of aryl hydrocarbon receptor gene in patients with acromegaly. Clin Endocrinol 81:249–253CrossRef

56.

Cannavò S, Ragonese M, Puglisi S, Romeo PD, Torre ML, Alibrandi A, Scaroni C, Occhi G, Ceccato F, Regazzo D, De Menis E, Sartorato P, Arnaldi G, Trementino L, Trimarchi F, Ferrau F (2016) Acromegaly is more severe in patients with AHR or AIP gene variants living in highly polluted areas. J Clin Endocrinol Metab 101:1872–1879CrossRefPubMed

57.

Moran TB, Brannick KE, Raetzman LT (2012) Aryl-hydrocarbon receptor activity modulates prolactin expression in the pituitary. Toxicol Appl Pharmacol 265:139–145CrossRefPubMedPubMedCentral

58.

Huang P, Ceccatelli S, Håkansson H, Grandison L, Rannung A (2002) Constitutive and TCDD-induced expression of Ah receptor-responsive genes in the pituitary. NeuroToxicology 23:783–793CrossRefPubMed

59.

Huang P, Rannung A, Ahlbom E, Håkansson H, Ceccatelli S (2000) Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on the expression of cytochrome P450 1A1, the aryl hydrocarbon receptor, and the aryl hydrocarbon receptor nuclear translocator in rat brain and pituitary. Toxicol Appl Pharmacol 169:159–167CrossRefPubMed

60.

Mankidy R, Wiseman S, Ma H, Giesy JP (2013) Biological impact of phthalates. Toxicol Lett 217:50–58CrossRefPubMed

61.

Yoon BI, Hirabayashi Y, Kawasaki Y, Kodama Y, Kaneko T, Kanno J, Kim DY, Fujii-Kuriyama Y, Inoue T (2002) Aryl hydrocarbon receptor mediates benzene-induced hematotoxicity. Toxicol Sci 70:150–156CrossRefPubMed

62.

Gore AC, Crews D, Doan LL, La Merril M, Patisaul H, Zota A (2014) Introduction to endocrine disrupting chemicals (EDC). A guide for public interest organizations and policy-makers. The Endocrine Society and IPEN, pp 1–69. http://ipen.org/documents/introduction-endocrine-disrupting-chemicals-edcs

Title: Benzene and 2-ethyl-phthalate induce proliferation in normal rat pituitary cells
Authors: Laura Tapella
Antonella Sesta
Maria Francesca Cassarino
Valentina Zunino
Maria Graziella Catalano
Francesca Pecori Giraldi
Publication date: 01-06-2017
Publisher: Springer US
Published in: Pituitary / Issue 3/2017
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-016-0777-3

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Benzene and 2-ethyl-phthalate induce proliferation in normal rat pituitary cells

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2017

Chordoid glioma: A new paradigm of hypothalamic dysfunction?

Anti-pituitary antibodies against corticotrophs in IgG4-related hypophysitis

White matter involvement on DTI-MRI in Cushing’s syndrome relates to mood disturbances and processing speed: a case-control study

Cholesterol granulomas presenting as sellar masses: a similar, but clinically distinct entity from craniopharyngioma and Rathke’s cleft cyst

Two-dimensional speckle tracking echocardiography demonstrates no effect of active acromegaly on left ventricular strain

Expression of cell cycle regulators and biomarkers of proliferation and regrowth in human pituitary adenomas

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page